Table 1.
FBP1 expression and clinicopathological characteristics of 242 HCC patients
| Factors | FBP1low (n = 121) | FBP1high (n = 121) | P-value |
|---|---|---|---|
| Sex | |||
| Male | 106 | 107 | 0.843 |
| Female | 15 | 14 | |
| Age (years) | |||
| ≤50 | 60 | 61 | 0.898 |
| >50 | 61 | 60 | |
| HbsAg positive | |||
| Yes | 110 | 102 | 0.119 |
| No | 11 | 19 | |
| HCV positive | |||
| Yes | 1 | 1 | 1.000 |
| No | 120 | 120 | |
| ALT (IU/L) | |||
| <40 | 61 | 64 | 0.700 |
| ≥40 | 60 | 57 | |
| Tbil (μmol/L) | |||
| ≥17 | 44 | 33 | 0.129 |
| <17 | 77 | 88 | |
| ALB (g/L) | |||
| <35 | 9 | 5 | 0.271 |
| ≥35 | 112 | 116 | |
| AFP (ng/ml) | |||
| <20 | 23 | 38 | 0.026 |
| ≥20 | 98 | 83 | |
| Cirrhosis | |||
| Yes | 97 | 92 | 0.437 |
| No | 24 | 29 | |
| Tumour diameter | |||
| ≤5 cm | 36 | 48 | 0.105 |
| >5 cm | 85 | 73 | |
| Tumour capsule | |||
| Yes | 71 | 85 | 0.060 |
| No | 50 | 36 | |
| Satellite nodules | |||
| Yes | 48 | 28 | 0.006 |
| No | 73 | 93 | |
| PVTT | |||
| Yes | 29 | 15 | 0.020 |
| No | 92 | 106 | |
| Edmonson grade | |||
| I+II | 93 | 96 | 0.641 |
| III+IV | 28 | 25 | |
| TNM stage | |||
| I | 60 | 86 | 0.001 |
| II+III+IV | 61 | 35 | |
| BCLC stage | |||
| A | 62 | 87 | 0.001 |
| B+C | 59 | 34 | |
AFP alpha-fetoprotein, ALT alanine aminotransferase, ALB albumin, BCLC stage Barcelona Clinic Liver Cancer stage, FBP1 fructose-1,6-bisphosphatase 1, HBV hepatitis B virus, HCV hepatitis C virus, TNM stage tumour-node-metastasis stage, PVTT portal vein tumour thrombosis
All the bold P-value were less than 0.05